Stable injection formulation containing paclitaxel

Details Stable injection formulation containing paclitaxel Stable injection formulation containing paclitaxel

1999-09-20

2000-04-04

Jarvis, William R. A.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

A61K 31335

Patent

active

060462302

ABSTRACT:
This invention relates to a stable injection paclitaxel formulation having polyoxyethylene sorbitol oleic polyester as a main solubilizer, and appears to have less toxicity and greater stability compared to polyethoxylated castor oil-containing formulation which is clinically used all over the world. The formulation includes paclitaxel 30 mg, povidone 80 mg, oxyethylene sorbitol oleate 0.5 to 2.0 ml, (oxyethylene glycol).sub.15-20 fatty acid monoester 0.5 to 2.0 ml, polyethylene glycol 1.0 ml, and anhydrous alcohol 2.0 ml. The oxyethylene sorbitol oleate is either (oxyethylene).sub.60 sorbitol tetraoleate or (oxyehtylene).sub.45 sorbitol trioleate.

REFERENCES:
patent: 5681846 (1997-10-01), Trissel
patent: 5770222 (1998-06-01), Unger et al.
patent: 5877205 (1999-03-01), Andersson
patent: 5922754 (1999-07-01), Burchett et al.
patent: 5925776 (1999-07-01), Nikolayev et al.

Affiliated with

Also associated with

Rating

Stable injection formulation containing paclitaxel does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Stable injection formulation containing paclitaxel, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Stable injection formulation containing paclitaxel will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-365754